Key Takeaways:
Poolbeg Pharma PLC (AIM:POLB) shares rose as much as 10% on Tuesday after the biopharmaceutical company secured its first national patent in Australia for its lead drug candidate, POLB 001.
"The patent grant could not be better timed," Chief Executive Jeremy Skillington said, given the progress of the company's TOPICAL trial for the drug.
The patent, granted by IP Australia, covers the use of p38 MAPK inhibitors like POLB 001 for preventing and treating cytokine release syndrome (CRS), a serious side effect of some cancer immunotherapies. The grant is the first in a patent family that originated with a UK filing in January 2023.
The intellectual property protection strengthens the commercial case for POLB 001 ahead of potential licensing deals. The company is currently conducting its TOPICAL trial in multiple myeloma patients, with interim data expected in summer 2026.
Securing this patent de-risks the development pathway for POLB 001 and is a key part of the company's broader strategy for the asset. Investors will now be watching for further patent grants in other jurisdictions and the interim trial data in 2026 as the next major catalysts.
This article is for informational purposes only and does not constitute investment advice.
